Kalvista Pharmaceuticals Inc
Business Description
KalVista Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule protease inhibitors. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
KalVista Pharmaceuticals specializes in the development of novel therapies for diseases with significant unmet medical needs, particularly in the areas of hereditary angioedema (HAE) and diabetic macular edema (DME). The company*s mission is to improve the lives of patients suffering from these debilitating conditions by developing innovative and effective treatments.
One of the key therapeutic focuses of KalVista Pharmaceuticals is hereditary angioedema (HAE), a rare genetic disorder characterized by recurring episodes of severe swelling in various parts of the body. HAE affects an estimated 1 in 10,000 to 1 in 50,000 individuals worldwide. The company is developing oral HAE therapies that offer a more convenient and patient-friendly alternative to current injectable treatments.
In addition to HAE, KalVista Pharmaceuticals is actively engaged in the development of treatments for diabetic macular edema (DME), a leading cause of vision loss in patients with diabetes. DME is characterized by fluid accumulation in the macula, which leads to blurred vision and potential blindness. The company is developing intravitreal DME therapies that aim to reduce edema and improve visual function in affected patients.
KalVista Pharmaceuticals leverages its expertise in protease inhibitors to design and develop potent and selective small molecules that target specific proteases involved in the pathogenesis of HAE and DME. These proteases play a critical role in the generation of bradykinin, a protein that causes blood vessels to dilate, leading to the characteristic symptoms of HAE and the leakage of fluid into the macula in DME.
The company*s drug development pipeline includes several promising candidates, including KVD824, a highly selective inhibitor of plasma kallikrein for the treatment of HAE, and KVD001, a potent inhibitor of plasma kallikrein for the treatment of DME. KalVista Pharmaceuticals conducts rigorous preclinical and clinical studies to evaluate the safety, efficacy, and tolerability of its drug candidates, with the ultimate goal of obtaining regulatory approval and bringing these therapies to market.
Furthermore, KalVista Pharmaceuticals actively seeks strategic partnerships and collaborations with pharmaceutical companies and other research organizations to accelerate the development and commercialization of its pipeline. The company has forged partnerships with renowned institutions such as the University of Cambridge and has received financial support from prestigious organizations like the Cystic Fibrosis Foundation Therapeutics Inc. (CFFT).
In summary, KalVista Pharmaceuticals is a biopharmaceutical company dedicated to advancing the field of protease inhibition therapies for the treatment of hereditary angioedema and diabetic macular edema. With a robust pipeline of innovative drug candidates and a commitment to improving patient outcomes, the company is poised to make a significant impact on the lives of individuals suffering from these challenging conditions.
|